Safety and tolerability of rizatriptan

Cephalalgia, Supplement

Volumn 20, Issue 1, 2000, Pages 16-18

  Sakai, F ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RIZATRIPTAN;

ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; MIGRAINE; NAUSEA; PARESTHESIA; SOMNOLENCE; THORAX PAIN; VERTIGO; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 0034454994     PISSN: 08001952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Rizatriptan versus sumatriptan in the acute treatment of migraine
2. Double-bind, placebo-controlled, dose-finding study of rizatriptan (MK462) in the acute treatment of migraine
3. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled outpatient study
4. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine
5. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
6. Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine
7. Comparison of rizatriptan 10 mg vs zolmitriptan 2.5 mg in migraine
8. Efficacy and safety of rizatriptan versus standard care during long term treatment for migraine